[go: up one dir, main page]

MA37829A1 - Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha - Google Patents

Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Info

Publication number
MA37829A1
MA37829A1 MA37829A MA37829A MA37829A1 MA 37829 A1 MA37829 A1 MA 37829A1 MA 37829 A MA37829 A MA 37829A MA 37829 A MA37829 A MA 37829A MA 37829 A1 MA37829 A1 MA 37829A1
Authority
MA
Morocco
Prior art keywords
inhibitor
egfr
optionally
raf
pharmaceutical combinations
Prior art date
Application number
MA37829A
Other languages
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure Moutouh-De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37829A1 publication Critical patent/MA37829A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une combinaison pharmaceutique comprenant (a) un inhibiteur de b-raf, (b) un inhibiteur d'egfr et facultativement (c) un inhibiteur de pi3k ; les utilisations d'une telle combinaison dans le traitement de maladies de prolifération ; et des méthodes de traitement d'un sujet souffrant d'une maladie de prolifération comprenant l'administration d'une quantité thérapeutiquement efficace d'une telle combinaison.
MA37829A 2012-08-07 2015-02-04 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha MA37829A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (fr) 2012-08-07 2013-08-05 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Publications (1)

Publication Number Publication Date
MA37829A1 true MA37829A1 (fr) 2017-01-31

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37829A MA37829A1 (fr) 2012-08-07 2015-02-04 Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha

Country Status (39)

Country Link
US (1) US9474754B2 (fr)
EP (2) EP3574904A1 (fr)
JP (3) JP6342396B2 (fr)
KR (1) KR102112885B1 (fr)
CN (1) CN104519887B (fr)
AR (1) AR092045A1 (fr)
AU (1) AU2013299841B8 (fr)
CA (1) CA2879548C (fr)
CL (1) CL2015000294A1 (fr)
CO (1) CO7200273A2 (fr)
CY (1) CY1122143T1 (fr)
DK (1) DK2882440T3 (fr)
EA (1) EA028420B1 (fr)
EC (1) ECSP15008695A (fr)
ES (1) ES2717911T3 (fr)
GT (1) GT201500025A (fr)
HK (1) HK1211831A1 (fr)
HR (1) HRP20190537T1 (fr)
HU (1) HUE042877T2 (fr)
IL (1) IL236934B (fr)
IN (1) IN2015DN00450A (fr)
JO (1) JOP20130236B1 (fr)
LT (1) LT2882440T (fr)
MA (1) MA37829A1 (fr)
MX (1) MX359403B (fr)
MY (1) MY176031A (fr)
NZ (1) NZ703940A (fr)
PE (2) PE20191655A1 (fr)
PH (1) PH12015500246A1 (fr)
PL (1) PL2882440T3 (fr)
PT (1) PT2882440T (fr)
RS (1) RS58734B1 (fr)
SG (1) SG11201500321YA (fr)
SI (1) SI2882440T1 (fr)
TN (1) TN2015000027A1 (fr)
TR (1) TR201904980T4 (fr)
TW (1) TWI607754B (fr)
UA (1) UA115786C2 (fr)
WO (1) WO2014025688A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500321YA (en) * 2012-08-07 2015-04-29 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EP2976106B1 (fr) 2013-03-21 2021-04-14 Array BioPharma Inc. Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur
WO2015145388A2 (fr) * 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
EA201790019A1 (ru) * 2014-06-16 2017-06-30 Уорлдуайд Иновейтив Нетуорк Способ выбора персонализированной трехкомпонентной терапии для лечения рака
WO2016193955A1 (fr) * 2015-06-04 2016-12-08 Giorgio Stassi Combinaisons d'inhibiteurs de kinase pour le traitement du cancer colorectal
CN107921026A (zh) * 2015-08-28 2018-04-17 诺华股份有限公司 药物组合物包含(a)α‑同种型特异性PI3K抑制剂alpelisib(BYL719)和(b)AKT抑制剂,优选MK‑2206,afuresertib或uprosertib及其在治疗/预防癌症中的应用
EP3355886A1 (fr) * 2015-08-28 2018-08-08 Novartis AG Combinaison pharmaceutique comprenant l'inhibiteur de pi3k alpélisib et l'inhibiteur de b-raf dabrafénib ; l'utilisation de cette combinaison dans le traitement ou la prévention du cancer
WO2017066664A1 (fr) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Polythérapie comprenant un inhibiteur de raf pour le traitement du cancer colorectal
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
KR102341660B1 (ko) * 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
JOP20200014A1 (ar) * 2017-08-03 2022-10-30 Novartis Ag توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (fr) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
BR112021022335A2 (pt) 2019-05-13 2021-12-28 Novartis Ag Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
US20250108051A1 (en) * 2022-01-27 2025-04-03 Tohoku University Therapeutic agent for cancer
WO2023230554A1 (fr) 2022-05-25 2023-11-30 Pfizer Inc. Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
TW202421133A (zh) * 2022-09-26 2024-06-01 美商馬布可爾公司 用於治療癌症的ｂ－ｒａｆ抑制劑和抗ｅｇｆｒ抗體之組合
WO2025003956A1 (fr) 2023-06-30 2025-01-02 Pfizer Inc. Formulations d'encorafénib à forte charge médicamenteuse

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR101626435B1 (ko) 2007-04-10 2016-06-01 엑셀리시스, 인코포레이티드 Ｐｉ３ｋ 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AU2010289794B2 (en) 2009-08-24 2014-10-02 Genentech, Inc. Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US20120202822A1 (en) * 2009-10-12 2012-08-09 Kurtis Earl Bachman Combination
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
AU2011328227B2 (en) * 2010-11-08 2015-04-09 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
WO2013070998A1 (fr) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center Traitement du cancer de l'ovaire par des 2-amino-4h-naphto[1,2-b]pyran-3-carbonitriles
BR112014011223A8 (pt) * 2011-11-11 2023-01-31 Novartis Ag Método de tratar uma doença proliferativa
SG11201500321YA (en) * 2012-08-07 2015-04-29 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Also Published As

Publication number Publication date
HK1211831A1 (zh) 2016-06-03
CA2879548C (fr) 2020-07-21
GT201500025A (es) 2017-09-28
ES2717911T3 (es) 2019-06-26
TN2015000027A1 (en) 2016-06-29
TWI607754B (zh) 2017-12-11
UA115786C2 (uk) 2017-12-26
HK1204976A1 (en) 2015-12-11
PH12015500246B1 (en) 2015-03-30
US9474754B2 (en) 2016-10-25
JP2018109022A (ja) 2018-07-12
KR102112885B1 (ko) 2020-05-19
MY176031A (en) 2020-07-22
EP2882440B1 (fr) 2019-02-27
CY1122143T1 (el) 2020-11-25
ECSP15008695A (es) 2019-03-29
AU2013299841A1 (en) 2015-02-12
PL2882440T3 (pl) 2019-07-31
JP6595024B2 (ja) 2019-10-23
LT2882440T (lt) 2019-04-25
IL236934B (en) 2018-11-29
NZ703940A (en) 2018-04-27
KR20150040905A (ko) 2015-04-15
TW201410247A (zh) 2014-03-16
CN104519887A (zh) 2015-04-15
JP2015524472A (ja) 2015-08-24
MX2015001732A (es) 2015-06-03
BR112015002384A8 (pt) 2023-01-31
WO2014025688A1 (fr) 2014-02-13
SG11201500321YA (en) 2015-04-29
PE20191655A1 (es) 2019-11-07
CN104519887B (zh) 2017-06-27
TR201904980T4 (tr) 2019-05-21
JP2020019780A (ja) 2020-02-06
PH12015500246A1 (en) 2015-03-30
RS58734B1 (sr) 2019-06-28
HUE042877T2 (hu) 2019-07-29
CL2015000294A1 (es) 2015-05-08
EA028420B1 (ru) 2017-11-30
CO7200273A2 (es) 2015-02-27
PE20150673A1 (es) 2015-05-20
DK2882440T3 (da) 2019-05-06
SI2882440T1 (sl) 2019-05-31
EP2882440A1 (fr) 2015-06-17
US20150265616A1 (en) 2015-09-24
AU2013299841B2 (en) 2016-11-24
AU2013299841A8 (en) 2017-01-05
CA2879548A1 (fr) 2014-02-13
EP3574904A1 (fr) 2019-12-04
BR112015002384A2 (pt) 2017-07-04
HRP20190537T1 (hr) 2019-06-28
JP6974669B2 (ja) 2021-12-01
PT2882440T (pt) 2019-04-23
IN2015DN00450A (fr) 2015-06-26
AR092045A1 (es) 2015-03-18
AU2013299841B8 (en) 2017-01-05
MX359403B (es) 2018-09-26
JP6342396B2 (ja) 2018-06-13
EA201590332A1 (ru) 2015-06-30
JOP20130236B1 (ar) 2021-08-17

Similar Documents

Publication Publication Date Title
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
MX2017005875A (es) Metodos para tratar enfermedades oculares.
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA033448B1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MA44612B1 (fr) Méthodes de traitement de cancers pédiatriques
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201000990A1 (ru) Лечение дисменореи путем трансдермального введения нестероидных противовоспалительных лекарственных средств
EA201200443A1 (ru) Комбинированное лекарственное средство и способ лечения венозных церебральных дисциркуляций
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA35927B1 (fr) Polythérapie pour le traitement d'un cancer de l'ovaire
MA38056A1 (fr) Inhibiteurs de la tyrosine kinase de bruton